
MyMD Pharmaceuticals has announced statistically significant positive topline results from a phase 2 trial of oral TNF- α inhibitor, MYMD-1 …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

